BAP1 mutations promote development of cancer across multiple tissue types and are associated with differential survival outcomes, for example worse outcomes in uveal melanoma, kidney renal clear cell carcinoma and hepatocellular carcinoma, but improved outcomes in mesothelioma (11–18). This evidence concerns the gene BAP1 and mesothelioma.